Chugai Pharmabody Research Pte. Ltd. ('CPR') was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis, (Geneo from September 2026) in
Singapore
, it aims to generate new antibody drugs based on Chugai's proprietary antibody engineering technologies, such as recycling antibody®, sweeping antibody®, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are underdevelopment. Position - Senior Scientist in
Cell Biology and Technology Unit CPR is seeking a Senior Scientist with deep expertise in cell biology or pharmacology to advance regenerative medicine and cardiovascular/ metabolic (CVM) drug discovery, as well as to help shape novel therapeutic concepts. Reporting to the Research Manager, you will lead multidisciplinary projects from concept through execution, develop and validate...